Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Citius Oncology ( (CTOR) ).
On March 31, 2026, Citius Oncology reported early commercial traction for LYMPHIR (denileukin diftitox-cxdl) in the U.S. following its December 2025 launch for relapsed or refractory cutaneous T-cell lymphoma. The company highlighted sequential order growth, repeat purchasing by initial accounts and strong institutional uptake, with 83% of target cancer centers having added or progressing LYMPHIR through formulary review.
Market access is advancing, with about 135 health plans representing roughly 80% of covered lives providing coverage and no reported reimbursement denials or prior authorization barriers to date. Citius is also moving beyond major centers into community infusion sites, expanding its field force and running medical education and digital campaigns to support wider clinical integration.
Commercial supply is described as adequate to meet anticipated U.S. demand, while international expansion is underway via distribution agreements in Europe and the Middle East. In parallel, Citius is broadening LYMPHIR’s clinical footprint through investigator-sponsored studies, including a pre–CAR-T use in diffuse large B-cell lymphoma at the University of Minnesota and a completed Phase I combination study with pembrolizumab in solid tumors at UPMC.
Positive topline data from these early-stage studies have been presented or submitted for presentation at major oncology meetings, with further analyses and next-stage development discussions ongoing. Together, the commercial progress and expanding clinical program signal that LYMPHIR is gaining a foothold in the CTCL treatment landscape while positioning Citius Oncology to explore broader immuno-oncology combination opportunities.
The most recent analyst rating on (CTOR) stock is a Sell with a $0.48 price target. To see the full list of analyst forecasts on Citius Oncology stock, see the CTOR Stock Forecast page.
Spark’s Take on CTOR Stock
According to Spark, TipRanks’ AI Analyst, CTOR is a Neutral.
The score is primarily held down by weak financial performance (no revenue, widening losses, and worsening cash burn) and bearish technicals (below key moving averages with negative momentum). Positive early Phase 1 updates provide some upside optionality, but do not offset near-term funding and trend risks; valuation metrics offer limited support due to ongoing losses.
To see Spark’s full report on CTOR stock, click here.
More about Citius Oncology
Citius Oncology, Inc. is an oncology-focused biopharmaceutical company and majority-owned subsidiary of Citius Pharmaceuticals, Inc. The company develops and commercializes novel targeted oncology therapies, led by LYMPHIR, an FDA-approved treatment for adults with relapsed or refractory Stage I–III cutaneous T-cell lymphoma who have received at least one prior systemic therapy.
Management estimates LYMPHIR’s initial market opportunity exceeds $400 million and remains underserved by current treatments. Citius Oncology’s competitive positioning is supported by orphan drug protections, complex technology, trade secrets and pending patents, including for potential use in combination immuno-oncology regimens.
Average Trading Volume: 282,823
Technical Sentiment Signal: Sell
Current Market Cap: $43.52M
Learn more about CTOR stock on TipRanks’ Stock Analysis page.